Literature DB >> 19958929

Determinants of survival in patients with calciphylaxis: a multivariate analysis.

Geeta Lal1, Andrew G Nowell, Junlin Liao, Sonia L Sugg, Ronald J Weigel, James R Howe.   

Abstract

BACKGROUND: Our study aims to assess the factors affecting survival in patients with calciphylaxis.
METHODS: We identified 26 patients with biopsy-proven calciphylaxis treated between 1995 and 2007. Clinical and follow-up data were obtained from medical records. Cox proportional hazards models were used to assess the factors affecting survival.
RESULTS: The study group consisted of 23 women and 3 men with a mean age of 56.4 +/- 12.9 years. All patients had multiple comorbidities/risk factors including coronary artery disease (58%), diabetes mellitus (58%), and peripheral vascular disease (23%). Mean laboratory values were: calcium, 9.0 mg/dL (range, 6.8-11.6); albumin, 2.8 mg/dL; phosphate, 4.5 mg/dL (range, 2.5-7.5); Ca *phosphate, 35.9; and parathyroid hormone, 320.9 pg/mL (range, 4.6-2,419). Parathyroidectomy was performed in 9 of 26 patients (35%). Of our patients, 19% underwent revascularization procedures and 58% underwent debridement. In multivariate analyses, factors associated with poor survival were female gender ( P = .01), increased weight ( P = .01), and need for vascular procedures ( P = .06). Improved survival was associated with operative debridement ( P = .01). Parathyroidectomy alone did not emerge as a determinant of patient survival, although there was a trend to improved survival when debridement and parathyroidectomy were combined ( P = .09).
CONCLUSION: Rather than a single intervention such as parathyroidectomy, a multidisciplinary approach involving early diagnosis, aggressive medical management, operative debridement, and parathyroidectomy may improve survival in calciphylaxis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958929     DOI: 10.1016/j.surg.2009.09.022

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

Review 1.  Calciphylaxis: diagnosis and clinical features.

Authors:  Matsuhiko Hayashi
Journal:  Clin Exp Nephrol       Date:  2013-02-21       Impact factor: 2.801

2.  [Calciphylaxis. Pathogenesis and therapy].

Authors:  N-P Hoff; B Homey
Journal:  Hautarzt       Date:  2011-07       Impact factor: 0.751

Review 3.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

Review 4.  [Cutaneous calciphylaxis].

Authors:  U Wollina
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

5.  Calcific uremic arteriolopathy: an underrecognized entity.

Authors:  Victoria Ann Kumar
Journal:  Perm J       Date:  2011

6.  Sodium Thiosulfate as a Treatment for Calciphylaxis.

Authors:  Natsinee Tangkijngamvong; Paweena Susantitaphong; Numphung Numkarunarunrote; Onanong Jearnsujitwimol; Pravit Asawanonda; Pawinee Rerknimitr
Journal:  J Clin Aesthet Dermatol       Date:  2021-10

7.  Perioperative Management of Calciphylaxis: Literature Review and Treatment Recommendations.

Authors:  Natalie Strand; Jillian Maloney; Samuel Wu; Molly Kraus; Rick Schneider; Diego Gomez; Steven Char
Journal:  Orthop Rev (Pavia)       Date:  2022-08-25

Review 8.  Calciphylaxis: a review.

Authors:  Cynthia M Magro; Richard Simman; Sarah Jackson
Journal:  J Am Col Certif Wound Spec       Date:  2011-03-27

Review 9.  Cutaneous manifestations of ESRD.

Authors:  Timur A Galperin; Antonia J Cronin; Kieron S Leslie
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

10.  Update on cutaneous calciphylaxis.

Authors:  Uwe Wollina
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.